WeVote
Log In

Bill

Bill

S 2391

Provides dedicated funding for New Jersey Commission on Cancer Research from Workforce Development Partnership Fund.

2026-2027 Regular Session Introduced by Tony Bucco

Bill redirects New Jersey Workforce Development Partnership Fund money to cancer research commission, trading job training resources for medical research advancement.

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee
0
WeVote Research Nonpartisan
Bill Summary · S 2391

Legislative bill overview

S 2391 establishes dedicated funding for the New Jersey Commission on Cancer Research by allocating resources from the Workforce Development Partnership Fund. The bill designates a revenue stream that would otherwise support workforce development programs specifically toward cancer research initiatives and operations.

Why is this important

Cancer research funding directly impacts drug development, treatment innovation, and potentially survival rates for New Jersey residents. However, this represents a direct reallocation of workforce development money, creating a tradeoff between investing in job training programs versus medical research—both of which have significant public health implications.

Potential points of contention

  • Workforce development impact: Diverting funds from the Workforce Development Partnership Fund could reduce resources available for job training, vocational programs, and employment services that help unemployed and underemployed workers
  • Funding clarity: The bill's language doesn't specify the exact dollar amount being redirected or how it affects existing workforce programs, making fiscal impact assessment difficult
  • Prioritization debate: Legislators may disagree on whether cancer research funding should come from general appropriations rather than reallocating from economic development initiatives

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.